Beyond efficacy: Pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 8, 2011, Pages 1285-1295

  Giorgi, Mariano A ^a   Cohen Arazi, Hernán ^a   Gonzalez, Claudio D ^a   Di Girolamo, Guillermo ^a  

^a FLENI   (Argentina)

Author keywords

antiplatelet agents; clopidogrel; pharmacodynamic; pharmacokinetics; prasugrel; ticagrelor

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450; PRASUGREL; TICAGRELOR;

AREA UNDER THE CURVE; BRAIN HEMORRHAGE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHARMACOGENETICS; REVIEW; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ADENOSINE; HUMANS; PIPERAZINES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STANDARD OF CARE; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79954624013     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.550573     Document Type: Review

References (65)

1. The Clopidogrel in unstable angina to prevent recurrent events trial investigators.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation.N Engl J Med 2001;345:494-502
2. Mehta SR, Yusuf S, Peters RJ, et al.Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.Lancet 2001;358:527-33 (Pubitemid 32772726)
3. Kushner FG, Hand M, Smith SC Jr, et al.2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American college of cardiology foundation/American heart association task force on practice guidelines.J Am Coll Cardiol 2009;54:2205-41
4. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).Eur Heart J 2010, doi:10.1093/eurheartj/ehq277.Available from: http://www.escardio.org/guidelines-surveys/esc-guidelines/Guidelines Documents/guidelines-revasc-FT.pdf [Last accessed 31 August 2010].
5. Combescure C, Fontana P, Mallouk N, et al.Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis.J Thromb Haemost 2010;8:923-33
6. Bonello L, Tantry US, Marcucci R, et al.Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.J Am Cardiol 2010;56:919-33
7. Wilkinson GR.Drug metabolism and variability among patients in drug response.N Engl J Med 2005;352:2211-21
8. Marin F, Gonzalez-Conejero R, Capranzano P, et al.Pharmacogenetics in cardiovascular antithrombotic therapy.J Am Coll Cardiol 2009;54:1041-57
9. Lordkipanidze M, Diodati JG, Pharand C.Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence.Pharmacol Ther 2009;123:178-86
10. Angiolillo DJ, Fernandez-Prtiz A, Bernardo E, et al.Variability in individual responsiveness to clopidogrel.J Am Coll Cardiol 2007;49:1505-16
11. Giorgi MA, Gonzalez CD, Di Girolamo.Nonresponders to clopidogrel: pharmacokinetics and interactions involved.Expert Opin Pharmacother 2010;11:2391-403
12. Angiolillo DJ, Capranzano P.Pharmacology of novel antiplatelet inhibitors.Am Heart J 2008;156:S10-15
13. Wallentin L, Varenhorst C, James S, et al.Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.Eur Heart J 2008;29:21-30
14. Springthorpe B, Bailey A, Barton P, et al.From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.Biorg Med Chem Lett 2007;17:6013-18 (Pubitemid 47446193)
15. Taubert D, von Beckerath N, Grimberg G, et al.Impact of P-glycoprotein on clopidogrel absorption.Clin Pharmacol Ther 2006;80:486-501 (Pubitemid 44767878)
16. Small DS, Farid NA, Li YG, et al.Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.Curr Med Res Opin 2008;24:2251-7
17. Teng R, Butler K.Pharmacokinetics, pharmacodynamics, tolerability, and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects.Eur J Clin Pharmacol 2010;66:487-96
18. Farid NA, Small DS, Payne CD, et al.Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.Pharmacotherapy 2008;28:1483-94
19. Farid NA, Kurihara A, Wrighton SA, et al.Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.J Clin Pharmacol 2010;50:126-42
20. Simon T, Verstuyft C, Mary-Krause M, et al.Genetic determinants of response to clopidogrel and cardiovascular events.N Engl J Med 2009;360:363-75
21. Mega JL, Close SL, Wiviott SD, et al.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.Lancet 2010; doi:10.1016/s0140-6736(10) 61274-3.Avalilable from: www.thelancet.com [Last accessed 22 November 2010]
22. Thebault JJ, Kieffer G, Cariou R.Single dose pharmacodynamics of clopidogrel.Semin Thromb Hemost 1999;25(Suppl 2):3-8
23. Mega JL, Close SL, Wiviott SD, et al.Cytochrome P450 genetic polymorphism and the response to prasugrel.Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.Circulation 2009;119:2553-60
24. Bahtt DL.COGENT: a prospective, randomized, placebo controlled trial of omeprazole in patients receiving aspirin and clopidogrel.Presented at Transcatheter Cardiovascular Therapeutics, 24 September 2009, San Francisco, CA, USA
25. Tang M, Mukundan M, Yang J, et al.Antiplatelet agents aspirin and clopidogrel are hydrolized by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol.J Pharamacol Exp Ther 2006;319:1467-76
26. Kazui M, Nishiya Y, Ishizuka T, et al.Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.Drug Metab Dispos 2010;38:92-9
27. Hulot JS, Bura A, Villard E, et al.Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Blood 2006;108:2244-7 (Pubitemid 44497506)
28. Giusti B, Gori AM, Marcucci R, et al.Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 +12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.Phamacogenet Genomics 2007;17:1057-64 (Pubitemid 351339490)
29. Shuldiner AR, OConnel JR, Bliden KP, et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.JAMA 2009;302:849-58
30. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug.Available from: http://www.fda.gov/drugs/drugsafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm203888.htm [Last accessed 21 July 2010]
31. Holmes DR, Dehmer GJ, Kaul S, et al.ACC/AHA clopidogrel clinical alert: approaches to the FDA Boxed Warning: a report of the American college of cardiology foundation task force on clinical expert consensus eocuments and the American heart association.J Am Coll Cardiol 2010;56:321-41
32. Collet JP, Hullot JS, Pena A, et al.Cytochrome P450 C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.Lancet 2009;373:309-17
33. Gilard M, Arnaud B, Cornily JC, et al.Influence of omeprazole on the antiplatelet action of associated with aspirin.The randomized, double-blind, OCLA (Omeprazole Clopidogrel Aspirin) study.J Am Coll Cardiol 2008;51:256-60
34. ODonoghue ML, Braunwald E, Antman EM, et al.Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials.Lancet 2009;374:989-97
35. Juurlink DN, Gomes T, Ko DT, et al.A population-based study of the drug interaction between proton-pump inhibitors and clopidogrel.CMAJ 2009;180:713-18
36. Ray WA, Murray KT, Griffin MR, et al.Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.Ann Intern Med 2010;152:393-5
37. Sibbing D, Kastrati A.Risk of combining PPIs with thienopyridines: fact or fiction? Lancet 2009;374:952-4
38. European medicines agency.Public statement on possible interaction between clopidogrel and proton-pump inhibitors.Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf [Last accessed 22 November 2010]
39. Food and drug administration.Public health advisory: updated safety information about a drug interaction between clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC).Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcare Professionals/ucm190787 [Last accessed 22 November 2010]
40. Abraham NS, Hlatky MA, Antman EM, et al.ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force.J Am Coll Cardiol 2010:56:2051-66
41. Lau WC, Waskell LA, Watkins PB, et al.Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.Circulation 2003;107:32-7 (Pubitemid 36070929)
42. Pereillo JM, Maftouh M, Andrieu A, et al.Structure and stereochemistry of the active metabolite of clopidogrel.Drug Metab Dispos 2002;30:1288-95 (Pubitemid 35265838)
43. Wiviott SD, Braunwald E, McCabe CH, et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes.N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
44. Prasugrel label information.Available from: www.dailymed.nlm.nih.gov/ dailymed/getfile.cfm? id12285&type=pdf&name=sfe91c18- c44b-48d7-1142-9668ae3df0c6 [Last accessed 20 November 2010]
45. Brandt JT, Payne CD, Wiviott SD, et al.A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.Am Heart J 2007;153:66, e9-e16
46. Rehmel JL, Eckstein JA, Farid NA, et al.Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.Drug Metab Dispos 2006;34:600-7
47. Farid NA, Payne CD, Small DS, et al.Cytocrhome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.Clin Pharmacol Ther 2007;81:735-41 (Pubitemid 46625113)
48. Small DS, Farid NA, Payne CD, et al.Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics of prasugrel and clopidogrel.J Clin Pharmacol 2008;48:475-84 (Pubitemid 351389118)
49. Farid NA, Small DS, Payne CD, et al.Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.Pharmacotherapy 2008;28:1483-94
50. Wallentin L, James S, Storey RF, et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.Lancet 2010, doi:10.1016/S0140-6736(10)61274-3.Available from: www.thelancet.com [Last accessed 29 August 2010]
51. Teng R, Oliver S, Hayes MA, et al.Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.Drug Metab Dispos 2010;38:1514-21
52. Wallentin L, Becker R, Budaj A, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med 2009;361:1045-57
53. Gurbel PA, Bliden KP, Butler K, et al.Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.Circulation 2009;120:2577-85
54. Husted S, Emanuelsson H, Heptinstall S, et al.Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.Eur Heart J 2006;27:1038-47
55. Butler K, Teng R.Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.Br J Clin Pharmacol 2010;70:65-77
56. Buonamicci P, Marcucci R, Migliorini A, et al.Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.J Am Coll Cardiol 2007;49:2312-17 (Pubitemid 46891710)
57. Geeganage C, Wilcox R, Bath PM.Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.BMC Med 2010;8:36
58. Montalescot G, Sideris G, Meuleman C, et al.A randomized comparison of high clopidogrel loading doses in patients with non-ST-elevation acute coronary syndromes: the ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial.J Am Coll Cardiol 2006;48:931-8 (Pubitemid 44292463)
59. Stone GW, White HD, Ohman EM, et al.Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators.Lancet 2007;369:907-19
60. The CURRENT-OASIS 7 Investigators.Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.N Engl J Med 2010;363:930-42
61. Mehta SR, Tanguay JF, Eikelboom JW, et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.Lancet 2010, doi:10.1016/S0140-6736(10) 61088-4.Available from: www.thelancet.com [Last accessed 2 September 2010]
62. Subherwal S, Bach RG, Chen AY, et al.Baseline risk of major bleeding in non-ST-elevation myocardial infarction: the CRUSADE (Can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines) bleeding score.Circulation 2009;119:1873-82
63. Berger JS, Fye CB, Harshaw Q, et al.Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery.J Am Coll Cardiol 2008;52:1693-701
64. Wiviott SD, Trenk D, Freilinger Al, et al.Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation - thrombolysis in myocardial infarction 44 trial.Circulation 2007;116:2923-32 (Pubitemid 350291199)
65. Lins R, Broekhuysen J, Necciari J, et al.Pharmacokinetic profile of 14C-labeled clopidogrel.Semin Thromb Hemost 1999;25(Suppl 2):29-33